Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after the FDA approved its Prolia biosimilar PONLIMSI, and regulators in the US and Europe accepted filings for a Xolair biosimilar candidate.

At a share price of US$30.82, Teva has seen short term share price returns move around recent headlines, while the 1 year total shareholder return of 128.97% and 3 year total shareholder return of about 2.7x point to strong longer term momentum.

If progress in biosimilars and branded drugs has your attention, it could be a good moment to broaden your watchlist with 31 healthcare AI stocks

With Teva trading at US$30.82, a 1 year total return near 129% and an indicated intrinsic discount of about 48%, the key question is whether there is still an opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 18.5% Undervalued

At a last close of $30.82 versus a fair value narrative around $37.82, Teva is framed as undervalued with that gap explained by detailed long term modeling.

The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.

Curious what has to happen for this valuation to hold up? The narrative leans on modest revenue growth, rising margins and a richer earnings multiple. The exact mix might surprise you.

Result: Fair Value of $37.82 (UNDERVALUED)

However, this depends on Teva managing heavy net debt of over US$15b and avoiding setbacks if key branded drugs or biosimilars underperform expectations.

Another Way To Look At Teva’s Valuation

The first narrative leans on long term earnings and cash flow, but the current P/E of 25.5x tells a different story. It sits above both the US Pharmaceuticals average of about 17x and Teva’s own fair ratio of 21.6x, which points to some valuation risk if sentiment cools.

Our DCF model provides a different perspective, with an estimated future cash flow value around $59.03 per share suggesting Teva trades at a steep discount to that long term view. The question for you is which lens feels more reasonable: the richer multiple today, or the longer dated cash flows.

Next Steps

With the story so mixed, between valuation upside and clear pressure points, it makes sense to move quickly and test the numbers yourself. A good place to start is by weighing these 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Teva has sharpened your focus, do not stop there, you could miss opportunities that better match your risk, income, or growth preferences.

• Target stronger value potential by scanning 58 high quality undervalued stocks that pair solid fundamentals with prices that still look reasonable.
• Build dependable income streams by reviewing 11 dividend fortresses that aim to provide higher yields with a focus on resilience.
• Prioritize resilience under pressure by checking 72 resilient stocks with low risk scores that score well on financial strength and stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.